Information Provided By: 
Fly News Breaks for September 29, 2016
GNCA
Sep 29, 2016 | 13:33 EDT
The Phase IIb trial of Genocea Biosciences' GEN-003 for the treatment of genital herpes, which is the third trial that reduced viral shedding, "firmly established" proof-of-mechanism for the drug, Cowen analyst Phil Nadeau tells investors in a research note. The analyst continues to view Genocea shares as "significantly undervalued" based on the potential for GEN-003. Nadeau keeps an Outperform rating on the shares with a $40 price target. Genocea is down 5% to $5.45 in afternoon trading.
News For GNCA From the Last 2 Days
There are no results for your query GNCA
